60 Degrees Pharmaceuticals Registers ACLR8-LR, A Phase IIB Study Of Tafenoquine For Treatment Of COVID-19, On ClinicalTrials.gov
Portfolio Pulse from Benzinga Newsdesk
60 Degrees Pharmaceuticals has registered a Phase IIB study of Tafenoquine for the treatment of COVID-19 on ClinicalTrials.gov. The study is named ACLR8-LR.
August 15, 2023 | 11:32 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
60 Degrees Pharmaceuticals, potentially linked to SXTP, has registered a Phase IIB study for a COVID-19 treatment. This could impact the company's stock positively if the study shows promising results.
The registration of a Phase IIB study for a potential COVID-19 treatment by 60 Degrees Pharmaceuticals could have a positive impact on the stock price of SXTP, if the two are linked. The potential for a new treatment for COVID-19 could increase investor interest and drive up the stock price, especially if the study shows promising results.
CONFIDENCE 70
IMPORTANCE 80
RELEVANCE 75